



# YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

## 宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

### Form of Proxy for the 2023 Third Extraordinary General Meeting to be held on Wednesday, 27 December 2023

Number of Shares Related to this Form of Proxy <sup>(Note 1)</sup>	Domestic Shares
	H Shares

I/We <sup>(Note 2)</sup> \_\_\_\_\_  
of (address) \_\_\_\_\_  
being the registered holder(s) of \_\_\_\_\_ domestic shares/H shares <sup>(Note 3)</sup>  
of RMB1.00 each in the share capital of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "Company") hereby appoint **the Chairman of the meeting**  
**or** \_\_\_\_\_ <sup>(Note 4)</sup>  
of (address) \_\_\_\_\_  
as my/our proxy to attend and vote for me/us and on my/our behalf at the 2023 third extraordinary general meeting of the Company (the "EGM") to be held at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the People's Republic of China (the "PRC") at 10:00 a.m. on Wednesday, 27 December 2023 (or at any adjournment thereof) in respect of the resolutions as set out in the notice of EGM dated 1 December 2023, as indicated hereunder and, if no indication is given, as my/our proxy thinks fit.

ORDINARY RESOLUTIONS		For <sup>(Note 5)</sup>	Against <sup>(Note 5)</sup>	Abstain <sup>(Note 5)</sup>
1.	(a) the execution of the Framework Agreement (as defined in the circular of the Company dated 1 December 2023) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Framework Agreement and the proposed annual caps for the R&D cooperation expenses as set out in the Circular be and are hereby approved.			
2.	the board of directors of the Company be and are hereby authorised to do all such acts and things and execute all documents as he/she considers necessary, desirable or expedient for the purpose of, or in connection with, the Review of the List of R&D cooperation projects (as defined in the circular of the Company dated 1 December 2023) or any matter related thereto.			

Date: \_\_\_\_\_

Signature <sup>(Note 6)</sup> \_\_\_\_\_

#### Notes:

- Please insert the number of shares of the Company registered in your name(s) to which this form of proxy relates. If a number is inserted, this form of proxy will be deemed to relate only to those shares. If no number is inserted, this form of proxy will be deemed to relate to all shares of the Company registered in your name(s) (whether alone or jointly with others).
- Please insert the full name(s) and address(es) as registered in the registers of members of the Company in **BLOCK LETTERS**.
- Please insert the number of shares of the Company registered in your name(s) and delete whichever is inapplicable.
- If any proxy other than the Chairman of the meeting of the Company is preferred, please strike out the words "**the Chairman of the meeting or**" and insert the name of the proxy desired in the space provided. A shareholder may appoint one or more proxies to attend and vote on his/her behalf. A proxy need not be a shareholder of the Company. Any alteration made to this form of proxy must be initialed by the person who signs it.
- Important: If you wish to vote for any resolution, please put a tick in the box marked "FOR" or insert the number of shares held by you. If you wish to vote against any resolution, please put a tick in the box marked "AGAINST" or insert the number of shares held by you. If no direction is given, your proxy may vote as he/she thinks fit. The shares abstained will be included in the counting of the required majority.
- This form of proxy must be signed by you or your attorney duly authorized in writing or, in the case of a corporation, must be either executed under its common seal or under the hand of its director or attorney or other officer duly authorized. In case of joint holders, this form of proxy may be signed by any of such joint holders.
- To be valid, this form of proxy and, if such proxy is signed by a person on behalf of the appointor pursuant to a power of attorney or other authority, a notarized copy of that power of attorney or other authority must be delivered, for holders of domestic shares of the Company, to the Company's board office at Securities Department, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the PRC, or for holders of H shares of the Company, to the Company's H share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong not less than 24 hours before the time for holding of the EGM or any adjournment thereof (i.e. before 10:00 a.m. on Tuesday, 26 December 2023). Please note that 26 December 2023 is not a working day in Hong Kong and Computershare Hong Kong Investor Services Limited's office will not be opened on this day for physical delivery of the form of proxy.
- Where there are joint holders of any share of the Company, any one of such persons may vote at the EGM, either in person or by proxy, in respect of such share as if he or she was solely entitled thereto, but if more than one of such joint holders are present at the EGM, in person or by proxy, that one of the said persons so present whose name stands first on the register in respect of such shares shall alone be entitled to vote in respect thereof. The vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding of such shares.
- Please be advised that completion and delivery of this form of proxy will not preclude you from attending and voting at the EGM or any of its adjournments in person should you so wish.
- Unless otherwise defined, capitalized terms used in this form of proxy shall have the same meaning as those defined in the circular of the Company dated 1 December 2023 (the "Circular").